<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04837261</url>
  </required_header>
  <id_info>
    <org_study_id>R20113</org_study_id>
    <nct_id>NCT04837261</nct_id>
  </id_info>
  <brief_title>Shortening Duration of Antiarrhythmic Medication for SVT in Infants</brief_title>
  <official_title>Shortening Duration of Antiarrhythmic Medication for SVT in Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tampere University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kuopio University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oulu University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Turku University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tampere University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The infants diagnosed with SVT are treated with antiarrhythmic medication to prevent the&#xD;
      recurrence of SVT. This prospective observational cohort study evaluates efficacy and safety&#xD;
      of shortening duration of antiarrhythmic medication to four months in infants with SVT.&#xD;
      Primary outcome is incidence of recurrent SVT in infants after 4 months of antiarrhythmic&#xD;
      medication compared to retrospectively reviewed cohort.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 15, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence of SVT after antiarrhythmic medication</measure>
    <time_frame>1 year follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with treatment failure</measure>
    <time_frame>4 months of antiarrhythmic medication</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of adverse events</measure>
    <time_frame>4 months of antiarrhythmic medication</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence of SVT after one year follow-up</measure>
    <time_frame>5 year</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Supraventricular Tachycardia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol</intervention_name>
    <description>3 mg/kg/d, divided in four doses when age less than 3 months and in three doses when age more than 3 months</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flecainide</intervention_name>
    <description>80 mg/m2/d</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amiodarone</intervention_name>
    <description>Single dose of 10 mg/kg/d 10-14 days, 5 mg/kg/d</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Infants age less than 6 months with SVT due to AVRT or AVNRT&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 6 months or less&#xD;
&#xD;
          -  Documented SVT due to AVRT or AVNRT&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 6 months&#xD;
&#xD;
          -  Ectopic atrial tachycardia&#xD;
&#xD;
          -  Atrial flutter&#xD;
&#xD;
          -  Atrial fibrillation&#xD;
&#xD;
          -  Permanent junctional reciprocating tachycardia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>6 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tuija Poutanen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tampere University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Minna Mecklin, MD</last_name>
    <phone>+358444728153</phone>
    <email>minna.mecklin@pshp.fi</email>
  </overall_contact>
  <location>
    <facility>
      <name>Central Finland Central Hospital</name>
      <address>
        <city>Jyväskylä</city>
        <state>Central Finland</state>
        <zip>40620</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ole Andersen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kokkola Central Hopsital</name>
      <address>
        <city>Kokkola</city>
        <state>Central Ostrobothnia</state>
        <zip>67200</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Minna Rahkonen, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Krista Björkman, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Kajaani Central Hospital</name>
      <address>
        <city>Kajaani</city>
        <state>Kainuu</state>
        <zip>87300</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jenny Karjalainen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hämeenlinna Central Hospital</name>
      <address>
        <city>Hämeenlinna</city>
        <state>Kanta-Häme</state>
        <zip>13530</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Riikka Turunen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lapland Central Hospital</name>
      <address>
        <city>Rovaniemi</city>
        <state>Lapland</state>
        <zip>96101</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Linda Rautiainen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>North Karelia Central Hospital</name>
      <address>
        <city>Joensuu</city>
        <state>North Karelia</state>
        <zip>80210</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Seppo Juuti, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oulu University Hospital</name>
      <address>
        <city>Oulu</city>
        <state>North Ostrobothnia</state>
        <zip>90220</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Markku Leskinen, MD</last_name>
      <email>markku.leskinen@ppshp.fi</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kuopio University Hospital</name>
      <address>
        <city>Kuopio</city>
        <state>North Savo</state>
        <zip>70029</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hanna Ruotsalainen, MD</last_name>
      <email>hanna.ruotsalainen@kuh.fi</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vaasa Central Hospital</name>
      <address>
        <city>Vaasa</city>
        <state>Ostrobothnia</state>
        <zip>65130</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johanna Uunila, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <state>Pirkanmaa</state>
        <zip>33520</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Minna Mecklin, MD</last_name>
      <phone>+358444728153</phone>
      <email>minna.mecklin@pshp.fi</email>
    </contact>
    <contact_backup>
      <last_name>Kaisa Ylänen, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Tuija Poutanen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lahti Central Hospital</name>
      <address>
        <city>Lahti</city>
        <state>Päijät-Häme</state>
        <zip>15850</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mikko Lavonius, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kymenlaakso Central Hospital</name>
      <address>
        <city>Kotka</city>
        <state>Region Of Kymenlaakso</state>
        <zip>48210</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ville Westerlund, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sakunta Central Hospital</name>
      <address>
        <city>Pori</city>
        <state>Satakunta</state>
        <zip>28500</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Johannes Nieminen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>South Karelia Central Hospital</name>
      <address>
        <city>Lappeenranta</city>
        <state>South Karelia</state>
        <zip>53130</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Krista Ahtiainen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seinäjoki Central Hospital</name>
      <address>
        <city>Seinäjoki</city>
        <state>South Ostrobothnia</state>
        <zip>60220</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kirsi Nuolivirta, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mikkeli Central Hospital</name>
      <address>
        <city>Mikkeli</city>
        <state>South Savo</state>
        <zip>50100</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lotta Mäkelä, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <state>Southwest</state>
        <zip>20521</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anita Arola, MD</last_name>
      <email>anita.arola@tyks.fi</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helsinki University Hospital</name>
      <address>
        <city>Helsinki</city>
        <state>Uusimaa</state>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anita Hiippala, MD</last_name>
      <email>anita.hiippala@hus.fi</email>
    </contact>
    <contact_backup>
      <last_name>Juha-Matti Happonen, MD</last_name>
      <email>juha-matti.happonen@hus.fi</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 7, 2021</study_first_submitted>
  <study_first_submitted_qc>April 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2021</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tachycardia, Supraventricular</keyword>
  <keyword>Anti-Arrhythmia Agents</keyword>
  <keyword>Arrhythmias, Cardiac</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Supraventricular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
    <mesh_term>Amiodarone</mesh_term>
    <mesh_term>Flecainide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

